RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
89 hedge funds and large institutions have $317M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 34 increasing their positions, 19 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
89
Holders Change
+9
Holders Change %
+11.25%
% of All Funds
2.02%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
19
Increased
34
Reduced
19
Closed
10
Calls
$258K
Puts
–
Net Calls
+$258K
Net Calls Change
+$634K
Top Buyers
| 1 |
LCM
Laurion Capital Management
New York
|
$14.7M |
| 2 |
BlackRock
New York
|
$34.1M |
| 3 |
DM
Deerfield Management
New York
|
$11M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
$5.82M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
$17.3M |
